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Abstract: The IMPACT survey queried physicians, caregivers, payors and members of 
the general public from 5 European countries (France, Germany, Italy, Spain and the 
United Kingdom) regarding their opinions towards screening for Alzheimer’s disease 
(AD) as part of a 30-minute Web-based questionnaire conducted between April and May 
2009. A larger proportion of caregivers (84%) and members of the general public (80%) 
than of physicians (56%) or payors (40%) viewed routine screening for AD as extremely 
or very important. When asked if everyone should be routinely screened for AD at age 
65, a smaller proportion of physicians (42%) and payors (44%) than members of the 
general public (81%) or caregivers (80%) agreed. These opinions were generally 
consistent across the 5 countries for each respondent group. A notable exception was 
physician respondents from Italy, where most primary care physicians and specialists 
actually favoured screening. Overall, primary care physicians had a more positive 
attitude towards screening than specialists. The most frequently cited reason given by 
those who did not favour routine screening at age 65 was screening inaccuracy. This 
article discusses these results in relation to what screening is, when to screen and the 
barriers to screening. Despite the majority of IMPACT respondents being in favour of 
screening for AD, the evidence to support the introduction of population screening for 
cognitive impairment is not available; however, the importance of optimal identification of 
AD and other dementias in primary care should be a priority for community health 
professionals and payors. In order to do this effectively, further work is required to 
identify good assessment guidelines for use during opportunistic screening for cognitive 
impairment in primary care. 
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Introduction 
Like most chronic conditions and complex syndromes, Alzheimer’s disease (AD) and 
other dementias are not always diagnosed for all people with the conditions and there is 
an increasing international consensus encouraging earlier and more timely identification 
of cognitive impairment (1). This reflects the professional view that earlier identification 
of cognitive impairment benefits patients through the prompt treatment with 
pharmaceutical agents (2, 3) and psycho-social interventions (4, 5). Consequently, 
families and caregivers, health care systems and society in general are perceived to 
benefit (6). The reported advantages from a wide range of studies involving professional 
and informal caregivers that have been systematically reviewed include a better 
understanding of the condition, an end to uncertainty, the ability to plan for the future and 
access to formal and informal support (7) Some older citizens have expressed concerns 
about being labelled cognitively impaired (8) and some people with a diagnosis of 
dementia have found it distressing and stigmatising (7, 9-12).. However the perspectives 
of older people at risk of becoming “a person with dementia” and of people with 
dementia have been significantly neglected in empirical research (7, 13, 14). Recently, 
older patients’ attitudes towards dementia screening were measured in primary care 
clinics in the United States and the United Kingdom (15). Despite significantly higher 
acceptance of dementia screening by patients in the United Kingdom than in the United 
States, for them a diagnosis of dementia carried a greater perceived impact on 
independence and suffering. 
 
The growing consensus for early detection of cognitive impairment raises the question of 
whether validated universal community- or primary care–based dementia screening 
programs would lead to more timely identification of cognitive impairment. Current 
guidance from the US Preventive Services Task Force concludes that the evidence of 
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screening (16) is insufficient to recommend for or against routine screening for dementia 
in older adults (17). Whether routine screening for cognitive impairment is appropriate 
therefore remains contested. The IMPACT survey queried physicians, caregivers, 
payors and members of the general public from 5 European countries regarding their 
opinions towards screening for AD. 
 
Methods 
Approximately 1800 respondents from the United Kingdom, France, Germany, Italy and 
Spain participated in a 30-minute Web-based questionnaire between April and May 
2009. The respondents included approximately 1000 from the general public, 500 
physicians (PCPs and neurologists), 250 caregivers and 50 payors, with approximately 
equal numbers of each group from each of the 5 countries.  
 
 All respondents were asked, “How important is it to do routine screening for AD 
for people aged 65 and over?” For this question, respondents could choose extremely 
important, very important, somewhat important, not very important and not important at 
all. They were also asked, “Once someone turns 65, do you believe everyone should be 
routinely screened for AD?” to which they could choose don’t know; yes, they should be 
screened or no, they don’t need to be screened. Physicians, caregivers and those from 
the general public who answered no to the second question were then asked why they 
should not be screened and given a list of possible reasons from which to choose (they 
could choose more than 1). Payors were not asked to give reasons why they did not 
believe everyone should be screened at age 65.  
 
Results 
Importance of routine screening for AD 
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Although a large majority of each group favored screening, a greater percentage of 
caregivers (97%) and members of the general public (97%) than physicians (83%) or 
payors (74%) viewed routine screening for AD as either extremely, very or somewhat 
important. The degree of importance of screening varied amongst the respondent 
groups. The vast majority of caregivers (84%) and the general public (80%) believed it 
was extremely or very important, whereas only 56% of physicians and 40% of payors felt 
that strongly (Fig. 1). The consensus was similar amongst physicians from each country, 
except for those from Italy, where the majority (80%) felt screening was extremely or 
very important. More primary care physicians (62%) than specialists (50%) thought 
screening was extremely or very important. This was true in France (54% vs 32%), 
Germany (64% vs 48%) and Spain (74% vs 44%). In the United Kingdom more 
specialists than primary care physicians (50% vs 38%) agreed. The majority of both 
primary care physicians (82%) and specialists (78%) from Italy thought screening is 
extremely or very important. The percentage of payors who felt screening was extremely 
or very important ranged from a low of 20% in Spain to a high of 80% in Germany. There 
was good agreement between caregivers from each country (78% to 88%) and amongst 
members of the general public from each country, except for France, where only 67% 
agreed that screening was extremely or very important. 
 
Routine screening at age 65 
When asked if everyone should be routinely screened for AD at age 65, fewer 
physicians (42%) and payors (44%) than members of the general public (81%) or 
caregivers (80%) agreed (Fig. 2). In France, Germany and the United Kingdom, more 
physicians were opposed to screening at age 65 than were in favour of it. In Italy, more 
than twice as many physicians favoured screening at age 65 (66%) than opposed it 
(31%), whilst in Spain they were equally divided (yes, 46%; no, 44%). More primary care 
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physicians (53%) than specialists (32%) favoured routine screening at age 65. Primary 
care physicians favouring screening ranged from 22% in the United Kingdom to 70% 
and 74% in Italy and Spain, respectively. Specialists favouring screening ranged from 
18% in Germany to 58% in Italy. Only in the United Kingdom were there more specialists 
(34%) than primary care physicians (22%) who favoured routine screening. Only 20% of 
payors from Italy or Spain favoured routine screening whereas 70% from Germany did. 
Amongst caregivers from individual countries, those who favoured routine screening 
ranged from 70% in Italy to 94% in France, while amongst the general public it ranged 
from 73% in Germany to 90% in Spain. 
 
Reasons for not screening 
The most frequently cited reasons given by physicians who did not favour routine 
screening at age 65 were screening inaccuracy (44%), cost too much (33%) and lack of 
treatment (24%) (Table 1). The most frequently cited reason for physicians from the 
United Kingdom (44%), Germany (42%), and Spain (66%) was screening inaccuracy, 
whereas for those from France it was lack of treatment (44%) and for those from Italy it 
was monetary cost (58%). Both primary care physicians (33%) and specialists (50%) 
most frequently cited screening inaccuracy as the reason to not routinely screen, 
followed by monetary cost (30% and 34%, respectively). Primary care physicians cited 
too much time (28%) more frequently than lack of treatment (18%), whereas it was the 
opposite with specialists (14% vs 28%).  
 
The top 3 reasons cited by the general public for not routinely screening were screening 
inaccuracy (29%), costs too much (19%) and it takes too much time (16%). For 
caregivers, they were screening inaccuracy (31%), nothing you can do if you know 
(31%) and monetary cost (28%). 
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Discussion 
The responses from participants in the IMPACT Internet survey suggest that some 
caregivers and members of the general public may have a more positive opinion of 
routine screening for AD than those physicians or payors who responded. Participant 
responses were generally consistent across the 5 countries for each group. A notable 
exception was the physician participants in Italy, where a majority of primary care 
physicians and specialists were in favour of screening. Overall, more primary care 
physicians than specialists were in favour of screening. The most frequently mentioned 
barriers to routine screening by physicians, caregivers and members of the general 
public were the absence of an effective screening procedure, cost and the lack of 
effective treatments.  
 
The IMPACT survey was an Internet survey that used selected volunteer panels of 
physicians, informal caregivers, general public and payors. The findings about opinions 
on screening for cognitive impairment may be unrepresentative of these 4 groups in the 
5 countries surveyed since panel members and respondents are self selected. However, 
these findings raise a number of interesting questions that contribute to the debate about 
the future of routine screening for cognitive impairment. 
What is screening? 
An assumption of the questions asked of participants within the IMPACT survey was that 
they had a shared understanding of what was meant by screening, an assumption that 
permeates much of the discussion about screening for cognitive impairment in the 
literature (18). The question, ”What is screening?” is not simply of academic interest 
since it has profound public policy implications for the way that any form of screening is 
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implemented with European health care systems. ”Health screening” is undertaken in a 
range of health care settings and at different points in the course of disease, and 
includes universal population screening, targeted population screening, opportunistic 
screening or case finding in primary care or inpatient and outpatient secondary care, and 
formal assessment in specialist inpatient and outpatient care settings. 
 
Population screening of the whole population is unusual and most often is focussed on 
specific population groups (e.g. women aged 50 years or over for breast cancer 
screening and men and women aged 60-69 years for bowel cancer screening in the 
United Kingdom). Population screening may be self-administered (e.g. bowel cancer 
screening) or require attendance at a community-based or specialist clinic (e.g. breast 
cancer screening). Opportunistic screening or case finding as a form of screening is 
routinely undertaken in primary and secondary care for a range of chronic conditions 
(e.g. hypertension and diabetes) for which good treatments exist and reliable clinical 
measurements or tests with good sensitivity and specificity are available. Primary and 
secondary well-person clinics and routine health checks provide the same opportunities. 
Full diagnostic assessments in specialist clinics and settings have also been described 
as screening. 
When should we screen? 
In supporting the case for or against screening there are 2 key considerations: ethics 
and practicalities (including cost). A policy brief on screening in Europe published by the 
World Health Organization (19) highlights 4 key criteria for screening: 1) the condition 
should be an important health problem with high prevalence and impact on individuals 
and society that should be easily recognizable during the latent or early symptomatic 
stage; 2) there should be a suitable diagnostic test that is available, safe and acceptable 
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to the target population; 3) there should be an accepted and established treatment or 
intervention and these should be available; 4) “The cost of case finding (including 
diagnosis and treatment) should be economically balanced in relation to possible 
expenditure on medical care as a whole.” There are long-established criteria for the 
evaluation of suitable screening ”tests.” They should be simple to perform and easy to 
interpret; acceptable to ”patients”; accurate; cost-effective; and have good reliability 
(repeatability), sensitivity and specificity (20).  
Barriers to screening for cognitive impairment 
Contemporary discussion about screening has focussed both on population screening of 
older adults for cognitive impairment (18) and the role of primary care (21). In terms of 
the recommendations made on screening for the European Union, cognitive impairment, 
AD and other dementias are unable to satisfy all the criteria identified.  
 
Importance 
There is no disagreement about the importance of cognitive impairment globally and its 
impact on individuals, families and societies (22), although given the lack of a ”gold 
standard” test, cognitive impairment is not easily recognized prospectively. The barrier of 
“no effective treatment” often cited may be debated, since treatments to reduce the 
decline in cognition, and the associated loss of function, at the earliest evidence of 
dementia could have benefits (6).  For many chronic conditions (high blood pressure, 
high cholesterol, COPD, Parkinson’s) existing treatments do not cure, but do help 
manage the symptoms of disease. 
 
Screening test 
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No generally acceptable test exists for use in population screening although there are a 
number of recommendations for use in primary care ”case finding” (23-30). A systematic 
review of screening tests of cognitive impairment in general populations and primary 
care is urgently required given the diversity of views expressed in recent papers. 
 
Cost effectiveness of treatment and interventions 
The evidence base for the cost-effectiveness of pharmacological treatments and non-
pharmacological psycho-social interventions for early cognitive impairment remains 
weak. Established pharmacological treatments and non-pharmacological psycho-social 
interventions exist but these are not universally available in all EU countries since their 
use remains contested on grounds of cost-effectiveness except for in people with 
moderate dementia (12). 
Conclusions 
Despite the majority of IMPACT respondents being in favour of screening for AD, the 
evidence to support the introduction of population screening for cognitive impairment is 
not available. However, the importance of optimal identification of AD and other 
dementias in primary care should be a priority for community health professionals and 
payors. In order to do this effectively, further work is required to identify good 
assessment guidelines for use during opportunistic screening of cognitive impairment in 
primary care. 
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Figure 1 
How important is screening for AD? 
Figure 2 
Do you believe everyone who turns 65 should be routinely screened for AD? 
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Table 1 
Reasons Given for not Routinely Screening at Age 65 
 Respondents, % 
Reason for not Screening MDs Caregivers General Public 
Screenings for AD are not accurate 44 31 29 
It will cost too much money 33 28 19 
There is no treatment for it 24 17 11 
It takes too much time 19 10 16 
There is nothing you can do if you know 12 31 9 
It would be depressing to know 12 10 13 
It is not necessary to detect early 11 10 8 
Other reason 18 17 25 
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Figure 2.  
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